{
   "source_x": "PMC",
   "title": "Progress on the induction of neutralizing antibodies against HIV-1",
   "doi": "http://dx.doi.org/10.2165/00063030-200923030-00001",
   "pmcid": "PMC3764985",
   "abstract": "The Human Immunodeficiency Virus Type -1 (HIV-1), the causative agent of AIDS in humans, is one of the most catastrophic pandemics to affect human health care in the latter 20(th) century. The best hope of controlling this pandemic is the development of a successful prophylactic vaccine. However, to date, this goal has proven to be exceptionally elusive. The recent failure of an experimental AIDS vaccine in a phase IIb study named the STEP trial, intended to solely elicit cell mediated immune responses against HIV-1, has highlighted the need for a balanced immune response consisting of not only cellular immunity but also a broad and potent antibody response which can prevent the infection of HIV-1. This article will review the efforts being made up to this point to elicit such antibody responses, especially with regards to the use of a DNA prime-protein boost regimen which has been proven to be a highly effective platform for the induction of neutralizing antibodies in both animal and early phase human studies.",
   "authors": [
      "['Vaine, Michael', 'Lu, Shan', 'Wang, Shixia']"
   ],
   "id": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764985"
}